Omeros Q4 net income $128.7M on $200M milestone; OMIDRIA royalties record $35.8M sales

OMEROS CORP

Q4 net loss from continuing ops $46.0M ($0.73/share) vs $54.8M loss in Q3; cash burn $26M.
Received $200M milestone from Rayner in Feb 2023; OMIDRIA Q4 royalties $17.9M on record $35.8M sales.
Cash and short-term investments $194.9M; accounts receivable $213M now collected; no SVB exposure.
Preparing narsoplimab BLA resubmission for TA-TMA; FDA meeting expected Q2 2023; ARTEMIS-IGAN data Q3 2023.
Initiated OMS906 trials in PNH (treatment-naïve and ravulizumab inadequate response) and C3G; OMS1029 quarterly dosing possible.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OMEROS CORP reported the year ended December 31, 2022 results: net income $47.4 million, EPS $0.76 per share.

Period: the year ended December 31, 2022
Net income: $47.4 million
EPS: $0.76 per share
Result: reported results

Exact text from the filing

For the year ended December 31, 2022, net income was $47.4 million, or $0.76 per share.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OMEROS CORP reported the fourth quarter ended December 31, 2022 results: net income $128.7 million, EPS $2.05 per share.

Period: the fourth quarter ended December 31, 2022
Net income: $128.7 million
EPS: $2.05 per share
Result: reported results

Exact text from the filing

Net income in the fourth quarter of 2022 was $128.7 million, or $2.05 per share, compared to a net loss in the third quarter of 2022 of $17.5 million, or $0.28 per share;

View on SEC.gov

Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-003572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.